Kura Oncology Grants Stock Options to New Employees, Supports Cancer Research Efforts.

Kura Oncology granted stock options to eight new employees under its 2023 Inducement Option Plan, supporting ongoing cancer research efforts. The options will have an exercise price of $5.60 per share and vest over four years. Kura Oncology's investigational therapy ziftomenib has received FDA Breakthrough Therapy Designation for relapsed/refractory NPM1-mutant acute myeloid leukemia, and a New Drug Application is pending.